Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12618000918224
Ethics application status
Approved
Date submitted
21/05/2018
Date registered
31/05/2018
Date last updated
17/10/2022
Date data sharing statement initially provided
8/02/2019
Date results provided
17/10/2022
Type of registration
Prospectively registered
Titles & IDs
Public title
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Query!
Scientific title
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
Query!
Secondary ID [1]
294614
0
NCT02046733
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
STIMULI
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Small Cell Lung Cancer
307447
0
Query!
Limited Stage Small Cell Lung Cancer
307448
0
Query!
Condition category
Condition code
Cancer
306534
306534
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
During the induction phase patients will receive nivolumab at a dose of 1 mg/kg intravenously followed (on the same day) by ipilimumab at a dose of 3 mg/kg intravenously once every 3 weeks for 4 cycles. This is followed by the maintenance phase. During this phase patients will receive nivolumab 240 mg intravenously once every 2 weeks for a maximum of 12 months from start of maintenance phase (no minimum time for the maintenance phase).
Query!
Intervention code [1]
300921
0
Treatment: Drugs
Query!
Comparator / control treatment
No Intervention: Observation - no further treatment
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
305540
0
Overall survival
Query!
Assessment method [1]
305540
0
Query!
Timepoint [1]
305540
0
From date of randomisation until death from any cause, assessed up to a maximum of 6,5 years
Query!
Primary outcome [2]
305541
0
Progression-free survival determined by RECIST 1.1
Query!
Assessment method [2]
305541
0
Query!
Timepoint [2]
305541
0
From date of randomisation until documented progression or death, if progression is not documented, assessed up to a maximum of 6,5 years
Query!
Secondary outcome [1]
345669
0
Objective response - Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from randomisation to termination of trial treatment.
Objective response to trial treatment will be determined using RECIST 1.1 criteria
Query!
Assessment method [1]
345669
0
Query!
Timepoint [1]
345669
0
From randomisation to termination of trial treatment, up to a maximum of 2 years
CT scans will happen on the following schedule:
• Up to 18 months: every 9 weeks
• Up to 2 years: every 12 weeks
Query!
Secondary outcome [2]
345670
0
Time to treatment failure defined by discontinuation of treatment for any reason (including progression of disease, treatment toxicity, refusal and death).
Query!
Assessment method [2]
345670
0
Query!
Timepoint [2]
345670
0
From date of randomisation until discontinuation of treatment for any reason, assessed up to a maximum of 6.5 years
Query!
Secondary outcome [3]
345671
0
Toxicity - toxicity reported by patients and by clinical assessment as assessed through adverse events classified according to NCI CTCAE version 4.
Query!
Assessment method [3]
345671
0
Query!
Timepoint [3]
345671
0
During Chemo-radiotherapy AEs will be assessed at baseline and at the end of each cycle of chemo-radiotherapy.
If patient is randomised, AEs will be assessed at randomisation,
Those in the experimental arm: end of each cycle of treatment;
Those in the Observation arm: weeks 9 and 18 and every 18 weeks thereafter;
End of treatment: within 7 days after end-of-treatment visit
100 days period after last treatment / last visit in observation arm.
If patient is not randomised AEs will be assessed at an end-of-treatment visit.
Up to a maximum of 6.5 years
Query!
Secondary outcome [4]
347522
0
Objective response to chemo-radiotherapy will be determined by tumour assessment around week 15.
Objective response to trial treatment will be determined using RECIST 1.1 criteria
Query!
Assessment method [4]
347522
0
Query!
Timepoint [4]
347522
0
Objective response to chemoradiotherapy this occur around Week 15 (post start of chemoradiotherapy)
Query!
Eligibility
Key inclusion criteria
At enrolment:
-Histologically or cytologically confirmed small cell lung carcinoma
-Untreated (with the exception of 1 cycle of chemotherapy given prior to enrolment) limited stage disease (LD) as defined by stage I-IIIB based on 7th TNM classifica-tion (IASLC classification for SCLC proposal). M0 proven by
-Whole body FDG-PET CT including a contrast-enhanced CT of thorax and upper abdomen (incl. liver, kidney, adrenals);
OR contrast-enhanced CT of thorax and upper abdomen (incl. liver, kidney, adrenals) and bone scan; AND
-Brain MRI (or contrast enhanced CT of the brain). Within 28 days before start of chemotherapy
-Age greater than or equal to 18 years
-ECOG performance status 0-1
-Adequate haematological, renal, hepatic and lung function
-Pulmonary function FEV1 of 1.0L or greater than 40% predicted value and DLCO greater than 40% predicted value
At randomisation:
-Chemo-radiotherapy completed per protocol: 4 cycles of chemotherapy, 85% of PTV of thoracic radiotherapy, as well as completed, mandatory PCI
-Non-PD after chemo-radiotherapy and PCI
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria at enrolment:
-Patients with mixed small-cell and non-small-cell histologic features
-Patients with pleural or pericardial effusions proven to be malignant
-Documented history of severe autoimmune or immune mediated symptomatic dis-ease that required prolonged (more than 2 months) systemic immunosuppressive treatment (e.g steroids) such as ulcerative colitis and Crohn´s disease, rheumathoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythemato-sus, or autoimmune vasculitis (eg, Wegener’s granulomatosis)
-Patients with an autoimmune paraneoplastic syndrome requiring concurrent immu-nosuppressive treatment are excluded.
-Interstitial lung disease or pulmonary fibrosis
-Women who are pregnant or in the period of lactation
-Patients with any concurrent anticancer systemic therapy (except for chemotherapy cycle 1)
-HIV, Hepatitis B or Hepatitis C infection
-Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast.
-Previous radiotherapy to the thorax (prior to inclusion)
-Planned mean lung dose greater than 20 Gy or V20 greater than 35%
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
30/06/2018
Query!
Actual
17/01/2019
Query!
Date of last participant enrolment
Anticipated
30/06/2020
Query!
Actual
29/04/2019
Query!
Date of last data collection
Anticipated
1/02/2022
Query!
Actual
28/02/2022
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
6
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
10929
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [2]
10930
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [3]
10931
0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Query!
Recruitment hospital [4]
10932
0
The Chris O’Brien Lifehouse - Camperdown
Query!
Recruitment hospital [5]
10933
0
Coffs Harbour Base Hospital - Coffs Harbour
Query!
Recruitment hospital [6]
10934
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [7]
10936
0
The Tweed Hospital - Tweed Heads
Query!
Recruitment hospital [8]
10937
0
Port Macquarie Base Hospital - Port Macquarie
Query!
Recruitment hospital [9]
10938
0
Riverina Cancer Care Centre - Wagga Wagga
Query!
Recruitment hospital [10]
10939
0
Epworth Richmond - Richmond
Query!
Recruitment hospital [11]
10940
0
Austin Health - Austin Hospital - Heidelberg
Query!
Recruitment hospital [12]
10941
0
Border Medical Oncology - Albury
Query!
Recruitment hospital [13]
10942
0
Peninsula Oncology Centre - Frankston
Query!
Recruitment hospital [14]
10943
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [15]
10944
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [16]
10945
0
The Townsville Hospital - Douglas
Query!
Recruitment hospital [17]
10946
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [18]
10947
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [19]
10948
0
Royal Hobart Hospital - Hobart
Query!
Recruitment postcode(s) [1]
22706
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
22707
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
22704
0
2065 - St Leonards
Query!
Recruitment postcode(s) [4]
22705
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
22709
0
2250 - Gosford
Query!
Recruitment postcode(s) [6]
22712
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [7]
22708
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [8]
22711
0
2485 - Tweed Heads
Query!
Recruitment postcode(s) [9]
22716
0
2640 - Albury
Query!
Recruitment postcode(s) [10]
22713
0
2650 - Wagga Wagga
Query!
Recruitment postcode(s) [11]
22715
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [12]
22714
0
3121 - Richmond
Query!
Recruitment postcode(s) [13]
22717
0
3199 - Frankston
Query!
Recruitment postcode(s) [14]
22718
0
4029 - Herston
Query!
Recruitment postcode(s) [15]
22719
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [16]
22721
0
4215 - Southport
Query!
Recruitment postcode(s) [17]
22720
0
4814 - Douglas
Query!
Recruitment postcode(s) [18]
22722
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [19]
22723
0
7000 - Hobart
Query!
Recruitment outside Australia
Country [1]
10295
0
New Zealand
Query!
State/province [1]
10295
0
Query!
Funding & Sponsors
Funding source category [1]
299233
0
Other Collaborative groups
Query!
Name [1]
299233
0
European Thoracic Oncology Platform
Query!
Address [1]
299233
0
c/o IBCSG Coordinating Centre,
Effingerstrasse 40,
CH- 3008 Bern
Query!
Country [1]
299233
0
Switzerland
Query!
Primary sponsor type
University
Query!
Name
NHMRC Clinical Trials Centre
Query!
Address
The University of Sydney
119-143 Missenden Road,
Camperdown, NSW 2050
Query!
Country
Australia
Query!
Secondary sponsor category [1]
298503
0
Other Collaborative groups
Query!
Name [1]
298503
0
European Thoracic Oncology Platform
Query!
Address [1]
298503
0
c/o IBCSG Coordinating Centre,
Effingerstrasse 40,
CH- 3008 Bern
Query!
Country [1]
298503
0
Switzerland
Query!
Other collaborator category [1]
280066
0
Other Collaborative groups
Query!
Name [1]
280066
0
Australasian Lung Cancer Trials Group
Query!
Address [1]
280066
0
Australasian Lung Cancer Trials Group
Lung Foundation Australia
Level 2, 11 Finchley Street
Milton, QLD 4064
Query!
Country [1]
280066
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
300155
0
Royal Prince Alfred Human Research Ethics Committee
Query!
Ethics committee address [1]
300155
0
Research Development Office Royal Prince Alfred Hospital Camperdown NSW 2050
Query!
Ethics committee country [1]
300155
0
Australia
Query!
Date submitted for ethics approval [1]
300155
0
22/01/2018
Query!
Approval date [1]
300155
0
10/04/2018
Query!
Ethics approval number [1]
300155
0
HREC/18/RPAH/5
Query!
Summary
Brief summary
The aim of the current study is to investigate whether adding nivolumab and ipilimumab after chemoradiotherapy helps to stop small cell lung cancer coming back. You may be eligible for this study if you are an adult with confirmed small cell lung carcinoma. If the study is suitable for you, you will commence treatment with chemotherapy and thoracic (chest) radiotherapy and prophylactic cranial irradiation (PCI/ brain) radiotherapy which are the standard of care treatment for SCLC. Following completion of the chemotherapy and radiotherapy part of your treatment you will have a CT scan to see if your cancer is shrinking or growing. If your cancer has grown your consulting doctor will discuss the most suitable treatment for you at that time. If your cancer has not grown, you will go on to the next part of the study, and you will be randomised into one of two study groups: Group 1: Nivolumab plus ipilimumab (experimental treatment) Group 2: Observation (no further treatment) If you take part in STIMULI, you will have a number of tests at the first study visit to confirm that the study is suitable for you. At each study visit, you will have various assessments, such as blood testing, urine testing. Computerised Tomography (CT) scans to assess your cancer will be performed every 2-3 months for the first 2 years and then less frequently. This study will help researchers understand how well this treatment works and how severe the side effects are of the standard treatment (chemotherapy and radiotherapy) alone, compared with the standard treatment (chemotherapy and radiotherapy) followed by immunotherapy (nivolumab and ipilimumab) in patients with limited SCLC.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
82722
0
A/Prof Paul Mitchell
Query!
Address
82722
0
Austin Hospital
145 Studley Road
Heidelberg, Vic, 3084
Query!
Country
82722
0
Australia
Query!
Phone
82722
0
+61 2 9562 5000
Query!
Fax
82722
0
Query!
Email
82722
0
STIMULI.study@sydney.edu.au
Query!
Contact person for public queries
Name
82723
0
Hannora Jurkovic
Query!
Address
82723
0
NHMRC Clinical Trials Centre, University of Sydney
119-143 Missenden Road, Camperdown NSW 2050
Query!
Country
82723
0
Australia
Query!
Phone
82723
0
+61 2 9562 5000
Query!
Fax
82723
0
Query!
Email
82723
0
STIMULI.study@sydney.edu.au
Query!
Contact person for scientific queries
Name
82724
0
Hannora Jurkovic
Query!
Address
82724
0
NHMRC Clinical Trials Centre, University of Sydney
119-143 Missenden Road, Camperdown NSW 2050
Query!
Country
82724
0
Australia
Query!
Phone
82724
0
+61 2 9562 5000
Query!
Fax
82724
0
Query!
Email
82724
0
STIMULI.study@sydney.edu.au
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Data will not be made publicly available. It will only be available to selected researchers at the discretion of ETOP. The researcher must make a formal request, which is reviewed by ETOP. The scientific merit and feasibility of each request will be evaluated and the decisions will be taken by ETOP on a case-by-case basis.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Study results article
Yes
Peters S. et al. 2022. Consolidation nivolumab and...
[
More Details
]
Documents added automatically
No additional documents have been identified.
Download to PDF